TRIAL DETAIL
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors |
|||
NCT#: |
||||
Conditions: |
Solid Tumors |
|||
Status: |
Terminated |
|||
Phase: |
1 |
Start Date 03/01/2014 |
Age of Trial (yrs) 10.2 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
MEK Inhibitor + CDK4/6 Inhibitor |
|||
Strategy: |
Block related tumor signal paths |
|||
Trial Type: |
GIST not specified. GIST patient enrollment unknown. |
|||
Other Protocol IDs: |
200344 |
|||
Sponsor: |
GlaxoSmithKline |
|||
Patient Contact: |
US GSK Clinical Trials Call Center
877-379-3718
GSKClinicalSupportHD@gsk.com |
|||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Oral |
|||
Trial Notes: |
Other Inclusion criteria for Part 1 Histologically or cytologically confirmed diagnosis of solid tumor malignancy that is not responsive to standard therapies or for which there is no approved or curative therapy. Exclusion Criteria: Prior treatment with a MEK inhibitor or a CDK4/6 inhibitor. BRAFV600 mutation positive. |
|||
Trial Links |
Trial Results |
Drug Information |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
1505 Holcombe Blvd. |
Houston |
TX |
77030 |
USA |
|
55 Fruit Street |
Boston |
MA |
02114 |
USA |
|
2220 Pierce Ave. |
Nashville |
TN |
37232 |
USA |